Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1-19 (Cancelled)

Claims 20 (Previously presented) A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a 5lipoxygenase selective inhibitor, a cyclosporin compound and a cyclooxygenase-2 selective inhibitor selected from flosutide 5-bromo-2-(4-fluorophenvl)-3-f4-(methvlsulfonvl)phenvll-thiophene, N-[2-cyclohexyloxv)-4-nitrophenvll-methanesulfonamide, 1,1-dioxide-4-hvdroxy-2-methvl-N-(5-methyl-2-thiazolvl)-2H-1,2-benzothiazine-3-carboxamide, N-[6-(2,4difluorophenoxv)-2,3-dihvdro-1-oxo-1H-inden-5-vl]-methanesulfonamide and compounds of Formula I or a pharmaceutically acceptable salt of a compound having Formula I:



(1)

wherein A is a 5-or 6-member ring substituent selected from partially unsaturated
or unsaturated heterocyclo and carbocyclic rings;

wherein R' is at least one substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R' is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;

wherein R^2 is selected from alkyl, and amino; and

wherein R^3 is a radical selected from halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclooxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclo, cycloalkenyl, aralkyl, heterocycloalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, arylaminocarbonyl, alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, arylamino, N-aralkylamino, N-alkyl-N-arylaminocarbonyl, alkyl-N-arylamino, aminoalkyl, alkylaminoalkyl, arylaminoalkyl, N-aralkylaminoalkyl, alkyl-Naralkylaminoalkyl, alkyl-N-arylaminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, arylaminosulfonyl, arylsulfonyl, and alkyl-N-arylaminosulfonyl.

Claim 21. (Cancelled)

Claim 22. (Previously presented) A composition comprising:

a 5-lipoxygenase selective inhibitor selected from the group consisting of: (Z)-5-Chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1 H-indole-1-carboxamide, (1-Benzo[b]thien-2-yl-ethyl)-N-hydroxyurea, 4-[2',4'-difluorbiphenyl]-4-oxomethyl-butanic acid, 6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2E)-N-[4[4-(diphenylmethyl)-1-pipe razinylJbutyl]-3-(6-methyl-3-pyridinyl)-2-propenamide, 1methyl-6-[[[3-(tetrahydro-4-methoxy-2-methyl-2H-pyran-4-yl)-2-propenyl]oxyJmethyl]2(1 H)-quinolinone, H yd roxy-N-[4- [3-(4-fl u o roph e noxy)p hen yl] -3-b utyn-2-yl]-u rea, N-[[5(4-fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N-hydroxyurea, [3-[5-(4-fluorophenoxy)-2-furanyl]-1-methyl-2-propynyl]-N-hydroxyurea, (R)-(+)-N-[3-[5-[(4fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea, [2-[[2-[(4'fluoro[1,1'-biphenyl]-4-yl)methyl]-1,2,3,4-tetrahydro-1-oxo-6-isoquinolinyl]oxy]ethyl]-Nhydroxy-urea, dihydro-4-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-methyl-2H-1,2oxazin-3(4H)-one, 4-(2-quinolylmethoxy)-N-(3-fluorobenzyl-phenyl-amino-methyl-4benzoic-acid, 6-

chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate, (2-[2-[1-(4chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1 Hthiopyrano[2,3,4-cd]indol-2-yl]ethoxy]-butanoic acid, [2,2-dimethyl-6-(4-chlorophenyl)-7phenyl-2, 3-dihydro-1 H-pyrrolizine-5-yl]-acetic acid, 1-([5-(3-methoxy-4-ethoxycarbonyloxyphenyl)-2,4-pentadienoyl]aminoethyl)-4-diphenylmethoxypiperidine, 2-[2,3-dihydro-1-methoxy-6-(2-naphthalenylmethoxy)-1 H-inden-1-yl]-thiazole, (6-[(3fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxymethyl]-1-ethyl-2quinolone, and 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yi])phenoxymethyl]-1-methyl-2-quinolone;

a cyclooxygenase-2 selective inhibitor selected from the group consisting of: 3-(3,4-difluorophenyl)-4-(4-methylsulfonylphenyl)-2-(5H)-furanone; 3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)-furanone; 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-m ethyl phenyl)-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(3-fluoro-4-methoxyphenyl)-3-(difluoromethyl)-1 H-pyrazol-1 yl]benzenesulfonamide;

3-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1 H-imidazol-2-yl]pyridine; 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4-trifluoromethyl-1 H-imidazol-2yl]pyridine;

4-[2-(5-meth ylpyridin-3-yi)-4-(trifluoromethyl)-1 H imidazol-1yl]benzenesulfonamide;

4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide; 4-[5-hydroxyethyl-3-phenylisoxazol-4 yl]benzenesulfonamide;

[2-trifluoromethyl-5-(3,4-difluorophenyl)-4-oxazolyl]benzenesulfonamide; 4-[2-methyl-4-phenyl-5-oxazolyl]benzenesulfonamide; and 4-[5-(3-fluoro-4-methoxyphenyl-2-trifluoromethyl)-4 oxazolyl]benzenesulfonamide; and

a cyclosporin compound.

Claim 23 (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 3-(3,4-difluorophenyl)-4-(4methylsulfonylphenyl)-2-(5H)-furanone.

Claim 24. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 3-phenyl-4-(4-methylsulfonylphenyl)-2-(5H)furanone.

Claim 25. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1 Hpyrazol-1-yl]benzenesulfonamide.

Claim 26. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-(4-methyl phenyl)-3-(trifluoromethyl)-1 Hpyrazol-1-yl]benzenesulfonamide.

Claim 27. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-(3-fluoro-4-methoxyphenyl)-3(difluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide.

Claim 28. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 3-[1-[4-(methylsulfonyl)phenyl]-4 trifluoromethyl 1 H-imidazol-2-yl]pyridine.

Claim 29. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 2-methyl-5-[1-[4-(methylsulfonyl)phenyl]-4trifluoromethyl-1 H-imidazol-2-yl]pyridine.

Claim 30. (Previously presented) The composition of claim 22 wherein

the cyclooxygenase-2 selective inhibitor is 4-[2-(5-methylpyridin-3-yl)-4-(trifluoromethyl)1 H-imidazol-1-yl]benzenesulfonamide.

Claim 31. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-methyl-3-phenylisoxazol-4yl]benzenesulfonamide.

Claim 32. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-hydroxyethyl-3-phenylisoxazol-4yl]benzenesulfonamide.

Claim 33. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is [2-trifluoromethyl-5-(3,4-difluorophenyl)-4oxazolyl]benzenesuifonamide.

Claim 34. (Previously presented) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[2-methyl-4-phenyl-5oxazolyl]benzenesulfonamide.

Claim 35. (Currently amended) The composition of claim 22 wherein the cyclooxygenase-2 selective inhibitor is 4-[5-(3-fluoro-4-methoxyphenyl-2trifluoromethyl)-4-oxazolyl]benzenesulfonamide.

Claim 36. (Previously presented) A composition comprising 4-[5-(4-methylpheny))-3-(trifluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide, N'-[[5-(4fluorophenoxy)furan-2-yl]-1-methyl-2-propynyl]-N'-hydroxyurea and a cyclosporin compound.

Claim 37. (Previously presented) A composition comprising 4-[5-(3-fluoro-4methoxyphenyl)-3-(difluoromethyl)-1 H-pyrazol-1-yl]benzenesulfonamide, N'-[[5-(4fluorophenoxy)furan-2-yl]-1-methyl-2-

propynyl]-N'-hydroxyurea and a cyclosporin compound.

Claim 38. (Previously presented) A composition comprising 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, N'-[[5-(4-fluorophenoxy)furan-2-yl]-1-methyl2-propynyl]-N'-hydroxyurea and a cyclosporin compound.